To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Ipilimumab + Nivolumab
Indication/Tumor Type head and neck squamous cell carcinoma
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive head and neck squamous cell carcinoma no benefit Ipilimumab + Nivolumab Phase III Actionable In a Phase III trial (CheckMate 651), first-line Opdivo (nivolumab) plus Yervoy (ipilimumab) treatment did not improve overall survival (17.6 vs 14.6 mo; HR=0.78) or objective response rate (34.1 vs 36.0%) compared to EXTREME (Erbitux (cetuximab) plus Platinol (cisplatin) or Paraplatin (carboplatin) plus Adrucil (fluorouracil) followed by Erbitux (cetuximab) maintenance) in recurrent/metastatic CD274 (PD-L1)-positive (CPS>=20) head and neck squamous cell carcinoma patients (PMID: 36473143; NCT02741570). 36473143
PubMed Id Reference Title Details
(36473143) Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. Full reference...